Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Robot-Assisted Training Versus Standard Training in Ischemic Stroke

NCT06273475 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2024-05-01
Last updated
2025-11-20

Condition(s) studied

StrokeIschemic Stroke

Investigational drug(s) / intervention(s)

Robot-assisted TrainingStandard Training

Robot-assisted Training: Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.

Standard Training: Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.

Study summary

The aim of this randomised controlled trial (RCT) nested in a prospective cohort, is to investigate the superior effect of late-phase robot-assisted versus standard training on motor function, physical function, fatigue, and quality of life in a moderately-to-severely impaired chronic stroke population following subacute rehabilitation.

The main hypothesis of the study is:

Robot-assisted training has a superior effect on motor function (Fugl-Meyer Lower Extremity Assessment; primary outcome), physical function, fatigue, and quality of life in moderately-to-severely impaired chronic stroke-affected individuals in comparison to standard training.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion: 1. Ischemic and haemorrhagic stroke 2. Chronic state (6-24 months post-stroke). 3. Subacute rehabilitation terminated (subacute phase defined as until 6 months post-stroke). 4. Moderately-severely impaired: 1. Modified Rankin Scale Score 3-5. 2. Scandinavian Stroke Scale Leg Motor Function Score 0-4 and/or SSS gait function 0-9. 5. Approved by referring doctor Exclusion: 1. Prior SAH 2. Infarct located in the cerebellum or brain stem 3. Severe fatigue making study completion improbable. 4. Cognitive deficits impeding study participation. 5. Inability to walk independently pre-stroke. 6. Recurrence of cardiovascular/cerebrovascular accidents. 7. Pre-existing neurological diseases or ongoing cancer treatment. 8. Refusing group allocation. 9. Concurrent participation in another clinical trial potentially interacting with the present trial.

Primary outcome measure(s)

  • Fugl-Meyer Lower Extremity Assessment of Motor Function — Pre-intervention (6-18 months post-stroke) and post-intervention (12-24 months post-stroke).
    The primary outcome measure is the between-group difference in change score of Fugl-Meyer Lower Extremity Assessment (FM-LE) from pre- (T6) to post-intervention (T12). The FM-LE assesses motor function and has been recommended as a part of a core outcome set in stroke rehabilitation studies.

Trial sites (2)

FacilityCityRegionStatus
Rigshospitalet and Herlev Gentofte Hospital Copenhagen Denmark Not Yet Recruiting
Odense University Hospital Odense Denmark Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06273475 on ClinicalTrials.gov ↗ ← All trials in Denmark